K562 In Vitro High-throughput Screening (HTS) Assay (CAT#: ITS-1022-YF200)

K562

Human

K562 cells are of the erythroleukemia type, and the cell line is derived from a 53-year-old female chronic myelogenous leukemia patient in blast crisis. The cells are non-adherent and rounded, are positive for the bcr:abl fusion gene, and bear some proteomic resemblance to both undifferentiated granulocytes and erythrocytes.

K-562

Chronic Myeloid Leukemia; CML

Oncology

In Vitro High-throughput Screening (HTS) Assay

K562-cell based In Vitro High-throughput Screening (HTS) Assay

HTS is one of the modern technologies used in cancer drug discovery. This technique enables to screen or assay thousands of chemical compounds against a target of interest within a short period. HTS is also useful in screening different libraries such as synthetic compounds, combinatorial chemistry, peptides and genomic libraries and obtaining toxicological and pharmacokinetic data related to chemical compounds. HTS has gained much attention among scientists and industries as a large number of compounds prepared by chemical synthesis methods can be screened within a short period, which can reduce the cost of drug discovery and animal use. HTS consist of major steps such as identification of targets, preparation of reagents, management of test compounds, development of suitable assay procedures and screening.

High-throughput Screening, High Content Screening and Reporter Gene Assays